Nanocarrier delivery has huge potential in agriculture; however, there are significant scientific and societal barriers to overcome. In this Review, the authors explore the state of the field, what lessons can be learned from nanomedicine, and discuss what scientific and societal issues need to be addressed.
How often should patients be screened for cannabis use? This is what a recent study published in JAMA Network Open hopes to address as a team of researchers from the University of California, Los Angeles (UCLA) investigated how primary care patients who recognize themselves as recreational cannabis users could potentially be at risk for—or suffering from—cannabis use disorder. This study holds the potential to raise awareness about healthcare providers conducting cannabis screening that could help identify early signs of cannabis use disorder in primary care patients.
For the study, the researchers analyzed surveys completed by 175,734 patients prior to a primary care appointment to assess their cannabis use and was conducted between January 2021 and March 2023. In the end, the researchers found that 17 percent indicated cannabis use in their surveys, of which 34.7 percent of those individuals demonstrated potentially high risk for cannabis use disorder based on their survey results. Additionally, 76.1 percent of patients indicated they used cannabis for medical reasons while not identifying as medical cannabis users. The researchers note these results indicate steps should be taken to conduct routine cannabis screenings of primary care patents by healthcare professionals.
“Patients may not tell their primary care providers about their cannabis use, and their doctors may not ask about it,” said Dr. Lillian Gelberg, MD, who is Professor in the Department of Family Medicine at the UCLA David Geffen School of Medicine and lead author of the study. “Not asking patients about their cannabis use results in a missed opportunity for opening up doctor-patient communication regarding use of cannabis generally and for management of their symptoms. ”
Discover an innovative ultra-thin battery for smart contact lenses, powered by tears and inspired by ‘Mission Impossible.’
Neuralink is onboarding patients in the UK in preparation for potential clinical trials amid a Brain-Computer Interface (BCI) boom.
Imagine a portable 3D printer you could hold in the palm of your hand. The tiny device could enable a user to rapidly create customized, low-cost objects on the go, like a fastener to repair a wobbly bicycle wheel or a component for a critical medical operation.
FUS instruments is a manufacturer of preclinical foucsed ultrasound systems for research. We specialize in systems for brain research. We sell stereotactic and MRI-guided FUS systems as well as transducer and other accessories for focused ultrasound research.
(Nanowerk News) Advanced technologies enable the controlled release of medicine to specific cells in the body. Scientists argue these same technologies must be applied to agriculture if growers are to meet increasing global food demands.
In a new Nature Nanotechnology journal review paper (“Towards realizing nano-enabled precision delivery in plants”), scientists from UC Riverside and Carnegie Mellon University highlight some of the best-known strategies for improving agriculture with nanotechnology.
GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK). The study included 42 patients suffering from mismatch repair deficient (dMMR) locally advanced rectal cancer, a type of bowel cancer.
Used as a first-line treatment and an alternative to chemotherapy and surgery, Jemperli cured cancer in all patients, showing “an unprecedented 100% clinical complete response rate.” Tests that followed showed no evidence of remaining tumors. Moreover, the first 24 of the 42 patients were observed after an average time of 26.3 months, and they showed no signs of cancer resurfacing.
GSK will test the drug in additional studies involving certain types of colorectal cancers.
Seedless blackberry, CRISPR.
US company introduces the world’s first seedless blackberry, revolutionizing fruit consumption and market dynamics.
